NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 319 filers reported holding NOVOCURE LTD in Q3 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,730,000 | +11.0% | 49,090 | +1.5% | 3.25% | -6.8% |
| Q2 2022 | $3,360,000 | -17.0% | 48,345 | -1.1% | 3.48% | +18.3% |
| Q1 2022 | $4,048,000 | +22.6% | 48,860 | +11.1% | 2.94% | +45.3% |
| Q4 2021 | $3,302,000 | -14.6% | 43,975 | +32.1% | 2.03% | -20.5% |
| Q3 2021 | $3,866,000 | -26.7% | 33,280 | +40.0% | 2.55% | -26.4% |
| Q2 2021 | $5,274,000 | +53.6% | 23,775 | -8.5% | 3.47% | +44.1% |
| Q1 2021 | $3,434,000 | -29.7% | 25,982 | -8.0% | 2.41% | -38.2% |
| Q4 2020 | $4,885,000 | +32.9% | 28,232 | -14.5% | 3.89% | +6.1% |
| Q3 2020 | $3,677,000 | +72.5% | 33,032 | -8.1% | 3.67% | +58.6% |
| Q2 2020 | $2,131,000 | -24.2% | 35,942 | -14.0% | 2.31% | -36.8% |
| Q1 2020 | $2,813,000 | -36.9% | 41,779 | -21.0% | 3.66% | -16.3% |
| Q4 2019 | $4,457,000 | – | 52,889 | – | 4.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |